Paul Hudson (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)

An FTC re­view of the Sanofi/Trans­late merg­er has a new dead­line af­ter agency calls for more time

The old say­ing goes, “good things come to those who wait”— but in Sanofi’s case, more wait­ing on US reg­u­la­tors to ap­prove its Trans­late Bio buy­out is like­ly far from a good thing.

On Aug. 27, Sanofi and Trans­late re­filed their pre­merg­er no­ti­fi­ca­tion with the FTC af­ter the agency in­di­cat­ed in “in­for­mal dis­cus­sions” that it need­ed more time to re­view the biotech and phar­ma gi­ant’s tie-up, Trans­late said in an SEC fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.